Feb 15, 2025 10:00PM
May 15, 2024 08:00AM
May 9, 2024 08:00AM
May 2, 2024 04:07PM
Mar 7, 2024 08:00AM
Dec 6, 2023 08:00AM
Dec 6, 2023 08:00AM Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD
Oct 30, 2023 08:09AM
Oct 30, 2023 08:00AM
Sep 26, 2023 08:01AM
Sep 26, 2023 08:01AM
Aug 21, 2023 08:03AM
Aug 21, 2023 08:00AM
Aug 10, 2023 08:01AM Phathom Pharmaceuticals Reports Second Quarter 2023 Results
Aug 9, 2023 06:44AM
Jun 12, 2023 08:02AM
Jun 12, 2023 08:01AM
Jan 3, 2023 05:20PM
Jan 3, 2023 04:03PM
Jan 3, 2023 04:02PM
Jan 3, 2023 04:01PM Phathom Pharmaceuticals Provides Update on New Drug Application Review of Vonoprazan for Erosive Esophagitis
Jan 3, 2023 04:01PM
Nov 8, 2022 05:00PM
Nov 8, 2022 05:00PM
Oct 21, 2022 08:46AM
Aug 2, 2022 08:00AM
Aug 2, 2022 08:00AM
May 25, 2022 08:06AM Phathom Pharmaceuticals Inc. (PHAT) Announces FDA Acceptance for Filing of Vonoprazan NDA for the Treatment of Erosive Esophagitis
May 25, 2022 08:00AM
May 25, 2022 08:00AM
May 4, 2022 07:22AM
Mar 3, 2022 06:58AM
Mar 2, 2022 06:34AM
Nov 8, 2021 08:00AM
Nov 8, 2021 08:00AM Phathom Pharmaceuticals Reports Third Quarter 2021 Results and Provides Key Clinical, Regulatory, and Business Updates

15,422 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All